Last reviewed · How we verify
EXPAREL Infiltration
At a glance
| Generic name | EXPAREL Infiltration |
|---|---|
| Also known as | Liposomal bupivacaine, Bupivacaine, Marcaine |
| Sponsor | Pacira Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population (PHASE2)
- Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery (PHASE4)
- A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction (PHASE4)
- Pectoralis and Serratus Muscle Blocks (PHASE4)
- Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine (NA)
- A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients (PHASE4)
- Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair (PHASE4)
- Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXPAREL Infiltration CI brief — competitive landscape report
- EXPAREL Infiltration updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI